A Real-World Experience in Pan-Tumor Testing for HER2 IHC in More Than 65 000 Solid Tumors
Menée à partir de l'analyse immunohistochimique de plus de 65 000 échantillons tumoraux couvrant différents sous-types de tumeurs solides (côlon-rectum, vessie, voies biliaires, poumon, endomètre, ovaire, col de l'utérus, pancréas...), cette étude évalue, en fonction du sous-type tumoral, l'expression de HER2 par type d'échantillon (échantillon biopsique ou pièce de résection)
Trastuzumab deruxtecan-nxki (T-DXd) was approved on April 5, 2024, by the US Food and Drug Administration for adults with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)–positive (immunohistochemistry [IHC] 3+) solid tumors who received systemic treatment and have no alternative treatment options. This tumor-agnostic approval was based on the objective response rate and duration of response in 192 patients with HER2 IHC 3+ tumors in 1 of 3 clinical trials (DESTINY-PanTumor02, DESTINY-Lung01, DESTINY-CRC02). Subtypes included colorectal (n = 64), bladder (n = 27), biliary tract (n = 22), lung (n = 17), endometrial (n = 16), ovarian (n = 15), cervical (n = 10), pancreatic (n = 5), and other tumors (n = 16). This study hypothesized that HER2 IHC 3+ prevalence would vary across tumor types within a real-world setting. Results are from a cohort of more than 65 000 patients with solid tumors who underwent pan-tumor HER2 IHC testing since the approval.
JAMA Oncology , article en libre accès, 2025